← Leaderboards
Lori A Coburn
Veterans Health Administration
$0
Attributed
$0
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $0 · FY2013–24$1$1$1$0$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
VA$0 · 3
By mechanism
I01$0 · 2
IK2$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Veterans Health Administration
Same institution · by research overlap
- Yash Choksi$650,614
- Jeffrey H Boatright$9,074,494
- Changhyon Chris Yun$11,920,592
- Didier Merlin$8,920,293
Others in their field
Top investigators on “Inflammation”
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$89,523,713
- David Heimbrook · Leidos Biomedical Research, Inc.$85,243,263
- Randall J Bateman · Washington University$64,707,456
- Peter Scott Heeger · Case Western Reserve University$56,547,884
Research focus
InflammationInjuryImmune ResponseInfiltrationInflammatory Bowel DiseasesColon CarcinomaHealthcare SystemsHistologicEotaxinEosinophilColorectal CancerEpithelial CellsAffectAzoxymethaneAmericanCytokineCrohn&AposCohortAdultColitisChemotactic FactorsCarcinogenesisApoptosisInsight
Grant awards (11)
The Role of CCL11 in Inflammatory and Sporadic Colorectal Cancer.$0
I01 · FY2024 · VA · contact PI
The Role of CCL11 in Inflammatory and Sporadic Colorectal Cancer.$0
I01 · FY2024 · VA · contact PI
CCL11 as a New Therapeutic Target for Colitis and Colon Cancer$0
I01 · FY2022 · VA · contact PI
CCL11 as a New Therapeutic Target for Colitis and Colon Cancer$0
I01 · FY2021 · VA · contact PI
CCL11 as a New Therapeutic Target for Colitis and Colon Cancer$0
I01 · FY2020 · VA · contact PI
CCL11 as a New Therapeutic Target for Colitis and Colon Cancer$0
I01 · FY2019 · VA · contact PI
Eotaxin in Colitis and Colitis-Associated Carcinogenesis$0
IK2 · FY2017 · VA · contact PI
Eotaxin in Colitis and Colitis-Associated Carcinogenesis$0
IK2 · FY2016 · VA · contact PI
Eotaxin in Colitis and Colitis-Associated Carcinogenesis$0
IK2 · FY2015 · VA · contact PI
Eotaxin in Colitis and Colitis-Associated Carcinogenesis$0
IK2 · FY2014 · VA · contact PI
Eotaxin in Colitis and Colitis-Associated Carcinogenesis$0
IK2 · FY2013 · VA · contact PI